Why should regulators consider using patient preferences in benefit-risk assessment?

doi:10.1007/s40273-013-0118-6

Editorial

. 2014 Jan;32(1):1-4.

doi: 10.1007/s40273-013-0118-6.

Why should regulators consider using patient preferences in benefit-risk assessment?

Janine A van Til¹, Maarten J Ijzerman

Affiliations

PMID: 24288209
DOI: 10.1007/s40273-013-0118-6

Editorial

Why should regulators consider using patient preferences in benefit-risk assessment?

Janine A van Til et al. Pharmacoeconomics. 2014 Jan.

. 2014 Jan;32(1):1-4.

doi: 10.1007/s40273-013-0118-6.

Authors

Janine A van Til¹, Maarten J Ijzerman

Affiliation

¹ Department of Health Technology and Services Research, University of Twente, PO Box 217, 7500 AE, Enschede, The Netherlands, j.a.vantil@utwente.nl.

PMID: 24288209
DOI: 10.1007/s40273-013-0118-6

No abstract available

PubMed Disclaimer

Cited by

Dynamics of Patient-Based Benefit-Risk Assessment of Medicines in Chronic Diseases: A Systematic Review.
El Masri H, McGuire TM, van Driel ML, Benham H, Hollingworth SA. El Masri H, et al. Patient Prefer Adherence. 2022 Sep 20;16:2609-2637. doi: 10.2147/PPA.S375062. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 36164323 Free PMC article. Review.
Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.
Fagery M, Khorshidi HA, Wong SQ, Vu M, IJzerman M. Fagery M, et al. Pharmacoeconomics. 2023 Oct;41(10):1229-1248. doi: 10.1007/s40273-023-01292-5. Epub 2023 Jun 23. Pharmacoeconomics. 2023. PMID: 37351802 Free PMC article.
Patient Involvement in the Lifecycle of Medicines According to Belgian Stakeholders: The Gap Between Theory and Practice.
Janssens R, van Overbeeke E, Verswijvel L, Meeusen L, Coenegrachts C, Pauwels K, Dooms M, Stevens H, Simoens S, Huys I. Janssens R, et al. Front Med (Lausanne). 2018 Oct 11;5:285. doi: 10.3389/fmed.2018.00285. eCollection 2018. Front Med (Lausanne). 2018. PMID: 30364285 Free PMC article.
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.
Wöckel A, Park-Simon TW, Korfel A, Raab K, Tesch H. Wöckel A, et al. Breast Cancer Res Treat. 2025 May;211(1):59-69. doi: 10.1007/s10549-025-07622-9. Epub 2025 Feb 20. Breast Cancer Res Treat. 2025. PMID: 39976865 Free PMC article.
Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US.
Whichello C, van Overbeeke E, Janssens R, Schölin Bywall K, Russo S, Veldwijk J, Cleemput I, Juhaeri J, Levitan B, Kübler J, Smith M, Hermann R, Englbrecht M, Hueber AJ, Comanescu A, Harding S, Simoens S, Huys I, de Bekker-Grob EW. Whichello C, et al. Front Pharmacol. 2019 Sep 18;10:1009. doi: 10.3389/fphar.2019.01009. eCollection 2019. Front Pharmacol. 2019. PMID: 31619989 Free PMC article.

See all "Cited by" articles

References

1. J Am Med Inform Assoc. 1998 May-Jun;5(3):257-62 - PubMed
1. Int J Technol Assess Health Care. 2004 Winter;20(1):92-6 - PubMed
1. Health Aff (Millwood). 2007 May-Jun;26(3):684-95 - PubMed
1. Ann Emerg Med. 1995 Aug;26(2):240-1 - PubMed
1. Pharmacoeconomics. 2006;24(5):419-23 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Other Literature Sources
- scite Smart Citations

[1] J Am Med Inform Assoc. 1998 May-Jun;5(3):257-62 - PubMed

[2] J Am Med Inform Assoc. 1998 May-Jun;5(3):257-62 - PubMed

[3] Int J Technol Assess Health Care. 2004 Winter;20(1):92-6 - PubMed

[4] Int J Technol Assess Health Care. 2004 Winter;20(1):92-6 - PubMed

[5] Health Aff (Millwood). 2007 May-Jun;26(3):684-95 - PubMed

[6] Health Aff (Millwood). 2007 May-Jun;26(3):684-95 - PubMed

[7] Ann Emerg Med. 1995 Aug;26(2):240-1 - PubMed

[8] Ann Emerg Med. 1995 Aug;26(2):240-1 - PubMed

[9] Pharmacoeconomics. 2006;24(5):419-23 - PubMed

[10] Pharmacoeconomics. 2006;24(5):419-23 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Why should regulators consider using patient preferences in benefit-risk assessment?

Affiliation

Why should regulators consider using patient preferences in benefit-risk assessment?

Authors

Affiliation

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources